Cargando…

Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics

BACKGROUND: Medication adherence is the main determinant of effective management of type 2 diabetes, yet there is no gold standard method available to screen patients with high-risk non-adherence. Developing machine learning models to predict high-risk non-adherence in patients with T2D could optimi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengting, Lu, Xiangyu, Yang, HengBo, Yuan, Rong, Yang, Yong, Tong, Rongsheng, Wu, Xingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714465/
https://www.ncbi.nlm.nih.gov/pubmed/36466490
http://dx.doi.org/10.3389/fpubh.2022.1000622
_version_ 1784842233131827200
author Li, Mengting
Lu, Xiangyu
Yang, HengBo
Yuan, Rong
Yang, Yong
Tong, Rongsheng
Wu, Xingwei
author_facet Li, Mengting
Lu, Xiangyu
Yang, HengBo
Yuan, Rong
Yang, Yong
Tong, Rongsheng
Wu, Xingwei
author_sort Li, Mengting
collection PubMed
description BACKGROUND: Medication adherence is the main determinant of effective management of type 2 diabetes, yet there is no gold standard method available to screen patients with high-risk non-adherence. Developing machine learning models to predict high-risk non-adherence in patients with T2D could optimize management. METHODS: This cross-sectional study was carried out on patients with T2D at the Sichuan Provincial People's Hospital from April 2018 to December 2019 who were examined for HbA1c on the day of the survey. Demographic and clinical characteristics were extracted from the questionnaire and electronic medical records. The sample was randomly divided into a training dataset and a test dataset with a radio of 8:2 after data preprocessing. Four imputing methods, five sampling methods, three screening methods, and 18 machine learning algorithms were used to groom data and develop and validate models. Bootstrapping was performed to generate the validation set for external validation and univariate analysis. Models were compared on the basis of predictive performance metrics. Finally, we validated the sample size on the best model. RESULTS: This study included 980 patients with T2D, of whom 184 (18.8%) were defined as medication non-adherence. The results indicated that the model used modified random forest as the imputation method, random under sampler as the sampling method, Boruta as the feature screening method and the ensemble algorithms and had the best performance. The area under the receiver operating characteristic curve (AUC), F1 score, and area under the precision-recall curve (AUPRC) of the best model, among a total of 1,080 trained models, were 0.8369, 0.7912, and 0.9574, respectively. Age, present fasting blood glucose (FBG) values, present HbA1c values, present random blood glucose (RBG) values, and body mass index (BMI) were the most significant contributors associated with risks of medication adherence. CONCLUSION: We found that machine learning methods could be used to predict the risk of non-adherence in patients with T2D. The proposed model was well performed to identify patients with T2D with non-adherence and could help improve individualized T2D management.
format Online
Article
Text
id pubmed-9714465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97144652022-12-02 Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics Li, Mengting Lu, Xiangyu Yang, HengBo Yuan, Rong Yang, Yong Tong, Rongsheng Wu, Xingwei Front Public Health Public Health BACKGROUND: Medication adherence is the main determinant of effective management of type 2 diabetes, yet there is no gold standard method available to screen patients with high-risk non-adherence. Developing machine learning models to predict high-risk non-adherence in patients with T2D could optimize management. METHODS: This cross-sectional study was carried out on patients with T2D at the Sichuan Provincial People's Hospital from April 2018 to December 2019 who were examined for HbA1c on the day of the survey. Demographic and clinical characteristics were extracted from the questionnaire and electronic medical records. The sample was randomly divided into a training dataset and a test dataset with a radio of 8:2 after data preprocessing. Four imputing methods, five sampling methods, three screening methods, and 18 machine learning algorithms were used to groom data and develop and validate models. Bootstrapping was performed to generate the validation set for external validation and univariate analysis. Models were compared on the basis of predictive performance metrics. Finally, we validated the sample size on the best model. RESULTS: This study included 980 patients with T2D, of whom 184 (18.8%) were defined as medication non-adherence. The results indicated that the model used modified random forest as the imputation method, random under sampler as the sampling method, Boruta as the feature screening method and the ensemble algorithms and had the best performance. The area under the receiver operating characteristic curve (AUC), F1 score, and area under the precision-recall curve (AUPRC) of the best model, among a total of 1,080 trained models, were 0.8369, 0.7912, and 0.9574, respectively. Age, present fasting blood glucose (FBG) values, present HbA1c values, present random blood glucose (RBG) values, and body mass index (BMI) were the most significant contributors associated with risks of medication adherence. CONCLUSION: We found that machine learning methods could be used to predict the risk of non-adherence in patients with T2D. The proposed model was well performed to identify patients with T2D with non-adherence and could help improve individualized T2D management. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9714465/ /pubmed/36466490 http://dx.doi.org/10.3389/fpubh.2022.1000622 Text en Copyright © 2022 Li, Lu, Yang, Yuan, Yang, Tong and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Li, Mengting
Lu, Xiangyu
Yang, HengBo
Yuan, Rong
Yang, Yong
Tong, Rongsheng
Wu, Xingwei
Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
title Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
title_full Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
title_fullStr Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
title_full_unstemmed Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
title_short Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
title_sort development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714465/
https://www.ncbi.nlm.nih.gov/pubmed/36466490
http://dx.doi.org/10.3389/fpubh.2022.1000622
work_keys_str_mv AT limengting developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics
AT luxiangyu developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics
AT yanghengbo developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics
AT yuanrong developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics
AT yangyong developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics
AT tongrongsheng developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics
AT wuxingwei developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics